Lenox Wealth Advisors Lowered Cathay General Banco (CATY) Holding by $1.37 Million as Market Value Declined; Baker Bros Advisors LP Has Trimmed Its Acorda Therapeutics (ACOR) Position as Stock Rose

May 24, 2018 - By Adrian Mccoy

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Logo

Lenox Wealth Advisors Inc decreased its stake in Cathay General Banco (CATY) by 99.72% based on its latest 2017Q4 regulatory filing with the SEC. Lenox Wealth Advisors Inc sold 34,300 shares as the company’s stock declined 8.67% with the market. The institutional investor held 98 shares of the major banks company at the end of 2017Q4, valued at $4,000, down from 34,398 at the end of the previous reported quarter. Lenox Wealth Advisors Inc who had been investing in Cathay General Banco for a number of months, seems to be less bullish one the $3.48 billion market cap company. The stock decreased 0.21% or $0.09 during the last trading session, reaching $42.87. About 292,476 shares traded. Cathay General Bancorp (NASDAQ:CATY) has risen 8.54% since May 24, 2017 and is uptrending. It has underperformed by 3.01% the S&P500.




Julian Baker decreased its stake in Acorda Therapeutics Inc. (ACOR) by 60.35% based on its latest 2017Q4 regulatory filing with the SEC. Baker Bros Advisors Lp sold 313,534 shares as the company’s stock rose 9.26% while stock markets declined. The hedge fund run by Julian Baker held 205,966 shares of the health care company at the end of 2017Q4, valued at $4.42 million, down from 519,500 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Acorda Therapeutics Inc. for a number of months, seems to be less bullish one the $1.09 billion market cap company. The stock increased 0.43% or $0.1 during the last trading session, reaching $23.25. About 290,388 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 10.61% since May 24, 2017 and is downtrending. It has underperformed by 22.16% the S&P500.

Among 10 analysts covering Cathay Bancorp (NASDAQ:CATY), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Cathay Bancorp had 36 analyst reports since July 22, 2015 according to SRatingsIntel. Keefe Bruyette & Woods maintained Cathay General Bancorp (NASDAQ:CATY) rating on Monday, September 25. Keefe Bruyette & Woods has “Hold” rating and $37.0 target. PiperJaffray upgraded the shares of CATY in report on Thursday, February 2 to “Overweight” rating. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, October 26. BMO Capital Markets downgraded the stock to “Hold” rating in Thursday, November 30 report. The stock has “Buy” rating by RBC Capital Markets on Tuesday, January 30. On Thursday, January 21 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Buy” rating by Piper Jaffray on Monday, July 10. The stock has “Hold” rating by BMO Capital Markets on Wednesday, April 18. On Thursday, April 21 the stock rating was maintained by DA Davidson with “Neutral”. Sandler O’Neill maintained Cathay General Bancorp (NASDAQ:CATY) on Thursday, March 29 with “Hold” rating.

Investors sentiment decreased to 1.23 in 2017 Q4. Its down 0.49, from 1.72 in 2017Q3. It dropped, as 14 investors sold CATY shares while 67 reduced holdings. 26 funds opened positions while 74 raised stakes. 53.28 million shares or 0.71% less from 53.66 million shares in 2017Q3 were reported. Millennium Mgmt Llc reported 0% stake. Jane Street Group Limited Liability Company reported 11,508 shares. Raymond James Associate holds 15,380 shares. Guggenheim Capital Lc holds 0.01% of its portfolio in Cathay General Bancorp (NASDAQ:CATY) for 62,123 shares. Comml Bank Of Mellon has invested 0.02% of its portfolio in Cathay General Bancorp (NASDAQ:CATY). Victory Cap Mngmt owns 6,492 shares or 0% of their US portfolio. Ameriprise Financial has 0.02% invested in Cathay General Bancorp (NASDAQ:CATY). Capital Rech Global Invsts invested in 1.00 million shares. Swiss Natl Bank, Switzerland-based fund reported 130,700 shares. First Citizens Fincl Bank And Co owns 5,485 shares or 0.03% of their US portfolio. New Mexico Educational Retirement Board has 18,800 shares for 0.03% of their portfolio. Weaver C Barksdale & Associates owns 75 shares for 0% of their portfolio. The Missouri-based Comm Bancshares has invested 0.01% in Cathay General Bancorp (NASDAQ:CATY). Opus Cap Group Ltd Liability reported 0.7% stake. Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 4,598 shares.

Since December 11, 2017, it had 0 buys, and 7 insider sales for $6.89 million activity. 1,000 Cathay General Bancorp (NASDAQ:CATY) shares with value of $43,400 were sold by BINGHAM KIM R. On Friday, February 2 WU PETER sold $1.47M worth of Cathay General Bancorp (NASDAQ:CATY) or 33,045 shares.

Another recent and important Cathay General Bancorp (NASDAQ:CATY) news was published by Globenewswire.com which published an article titled: “Market Trends Toward New Normal in Meritage, AllianceBernstein Holding, Viper Energy Partners LP, Huron …” on May 21, 2018.

Analysts await Cathay General Bancorp (NASDAQ:CATY) to report earnings on July, 18. They expect $0.87 EPS, up 35.94% or $0.23 from last year’s $0.64 per share. CATY’s profit will be $70.68M for 12.32 P/E if the $0.87 EPS becomes a reality. After $0.78 actual EPS reported by Cathay General Bancorp for the previous quarter, Wall Street now forecasts 11.54% EPS growth.

Lenox Wealth Advisors Inc, which manages about $648.86 million and $357.31 million US Long portfolio, upped its stake in Cisco Systems Inc (NASDAQ:CSCO) by 8,131 shares to 8,144 shares, valued at $312,000 in 2017Q4, according to the filing. It also increased its holding in Spdr S&P 500 Etf @ (SPY) by 8,171 shares in the quarter, for a total of 296,176 shares, and has risen its stake in Schwab Us Large Cap Etf (SCHX).

Analysts await Acorda Therapeutics, Inc. (NASDAQ:ACOR) to report earnings on July, 26. They expect $0.37 earnings per share, up 305.56% or $0.55 from last year’s $-0.18 per share. ACOR’s profit will be $17.41M for 15.71 P/E if the $0.37 EPS becomes a reality. After $-0.18 actual earnings per share reported by Acorda Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -305.56% EPS growth.

Investors sentiment decreased to 0.99 in 2017 Q4. Its down 0.23, from 1.22 in 2017Q3. It dived, as 24 investors sold ACOR shares while 46 reduced holdings. 23 funds opened positions while 46 raised stakes. 48.17 million shares or 6.13% less from 51.31 million shares in 2017Q3 were reported. Meeder Asset reported 1,837 shares. Teacher Retirement Systems Of Texas reported 0% stake. Moreover, Ls Investment Advsrs Limited Liability Corporation has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 1,435 shares. 1.04 million are held by Northern Tru Corporation. Pnc Group Inc Inc, a Pennsylvania-based fund reported 983 shares. Mason Street Advsrs Limited Liability Corporation accumulated 12,158 shares or 0.01% of the stock. Voya Investment Management Ltd Llc reported 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Fmr Ltd Liability invested in 0.01% or 5.84 million shares. Rhumbline Advisers has 108,011 shares. Martingale Asset Management Limited Partnership holds 37,332 shares or 0.01% of its portfolio. Manufacturers Life Insurance The stated it has 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Virginia Retirement Systems Et Al holds 0.01% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 37,400 shares. Group Incorporated One Trading Limited Partnership reported 13,175 shares stake. Alps accumulated 51,801 shares. Credit Suisse Ag holds 89,633 shares or 0% of its portfolio.

Since January 18, 2018, it had 0 insider buys, and 6 selling transactions for $3.05 million activity. $245,853 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares were sold by RAUSCHER STEVEN M. On Friday, January 19 the insider Wasman Jane sold $952,319. Shares for $854,911 were sold by LAWRENCE DAVID. The insider BLANK BURKHARD sold 25,000 shares worth $591,588. On Wednesday, May 2 the insider SMITH IAN F sold $237,175.

More news for Acorda Therapeutics, Inc. (NASDAQ:ACOR) were recently published by: Benzinga.com, which released: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” on April 29, 2018. Streetinsider.com‘s article titled: “Acorda Therapeutics (ACOR) Misses Q1 EPS by 33c, Revenues Miss” and published on May 02, 2018 is yet another important article.

Baker Bros Advisors Lp, which manages about $8.20 billion and $11.54 billion US Long portfolio, upped its stake in Gw Pharmaceuticals Plc (NASDAQ:GWPH) by 146,800 shares to 221,800 shares, valued at $29.28M in 2017Q4, according to the filing. It also increased its holding in Assembly Biosciences Inc. (NASDAQ:ASMB) by 72,727 shares in the quarter, for a total of 322,727 shares, and has risen its stake in Neurocrine Biosciences Inc. (NASDAQ:NBIX).

Cathay General Bancorp (NASDAQ:CATY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.